hepatitis C

Merck targets high-risk military veterans for hepatitis C lessons
Fierce Pharma
Mon, 10/16/17 - 11:55 am
Merck
hepatitis C
Zepatier
Merck Hepatitis C exit could lift the space’s two remaining drugmakers
Marketwatch
Sun, 10/1/17 - 10:04 am
Merck
hepatitis C
AbbVie
Gilead Sciences
The hep C pipeline shrivels as Merck dumps two next-gen combos, boosting leader Gilead
Endpoints
Fri, 09/29/17 - 10:03 am
Merck
hepatitis C
MK3682B
MK3682C
Gilead nabs Chinese nod for Sovaldi, eyeing world's largest hepatitis C patient base
Fierce Pharma
Tue, 09/26/17 - 10:03 am
China
Gilead Sciences
Sovaldi
hepatitis C
J&J moves away from hep C due to rival drugmakers' cures
BioPharma Dive
Mon, 09/11/17 - 10:28 pm
JNJ
hepatitis C
JNJ-4178
R&D
hepatitis B
J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market
Endpoints
Mon, 09/11/17 - 09:40 am
JNJ
Achillion
hepatitis C
odalasvir
ACH-3102
5 Things Gilead Sciences' Management Just Said That You'll Want to Know
Motley Fool
Thu, 09/7/17 - 09:40 am
Gilead Sciences
Kite Pharma
HIV
hepatitis C
M&A
Infographic | The leaders of the global hepatitis-C market
Medical Marketing and Media
Thu, 08/31/17 - 09:27 am
hepatitis C
Gilead Sciences
Merck
AbbVie
Bristol-Myers Squibb
Medivir out-licenses hep C drug to China’s Ascletis; Cellectis launches pioneering UCART123 US study
Endpoints
Sat, 08/19/17 - 10:29 am
Medvir
hepatitis C
China
Ascletis
Cellectis
UCART123
CAR-T
AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games
Marketwatch
Sun, 08/6/17 - 09:48 pm
AbbVie
hepatitis C
Mavyret
Gilead Sciences
Merck
Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?
Motley Fool
Sat, 08/5/17 - 09:44 am
AbbVie
Gilead Sciences
hepatitis C
Mavyret
AbbVie's new pan-genotypic hepatitis C drug Mavyret deeply underprices the competition
Fierce Pharma
Fri, 08/4/17 - 11:32 am
AbbVie
hepatitis C
Mavyret
drug pricing
5 Things Gilead Sciences' Q2 Earnings Numbers Didn't Tell You
Motley Fool
Mon, 07/31/17 - 09:59 pm
Gilead Sciences
earnings
hepatitis C
HIV
M&A
Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense
Motley Fool
Thu, 07/27/17 - 09:47 am
Gilead Sciences
AbbVie
hepatitis C
reorganization
Gilead Has Another Ace Up Its Sleeve
Seeking Alpha
Fri, 07/21/17 - 10:05 am
Gilead Sciences
hepatitis C
Vosevi
How AbbVie Could Hammer Gilead's Hepatitis C Franchise
Investors Business Daily
Wed, 07/19/17 - 07:55 pm
AbbVie
Gilead Sciences
hepatitis C
Vosevi
Harvoni
Sovaldi
Epclusa
Viekira Pak
When It Comes To Abusive Drug Pricing, Don't Confuse Shkreli With Hep C Drugs
Forbes
Wed, 07/19/17 - 09:58 am
drug pricing
hepatitis C
Martin Shkreli
Gilead Sciences
Harvoni
Sovaldi
FDA OKs a new triple hep C drug from Gilead, keeping its grip on a shrinking market
Endpoints
Tue, 07/18/17 - 10:55 pm
Gilead Sciences
FDA
hepatitis C
Vosevi
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Sat, 06/24/17 - 09:11 am
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda
Regulus reports a trio of pipeline setbacks
BioPharma Dive
Tue, 06/13/17 - 12:00 pm
Regulus
RG-101
RGLS5040
RG-105
cholestatic disease
type 2 diabetes
hepatitis C

Pages